Early-phase clinical trials operate under compressed timelines, complex protocols, narrow eligibility criteria and limited patient populations, making even small delays disproportionately costly. For emerging companies, where lean teams and critical development milestones heighten execution risk, traditional approaches to site feasibility and recruitment planning may no longer be sufficient. This webinar will explore how sponsors and CROs can improve enrollment predictability by integrating recruitment earlier into study design, protocol development, feasibility and site selection. Evidence-based feasibility can reduce reliance on historical site performance and questionnaire-driven projections by incorporating recruitable patient populations, investigator experience, prior trial performance, startup timelines, competing studies, referral networks, infrastructure and protocol-specific capabilities. The featured speakers will discuss the unique considerations and requirements that distinguish early-phase site selection from later-phase studies. The session will also examine the patient recruitment funnel and sources of attrition that occur well before enrollment. From diagnosis and referral through awareness, pre-screening, testing, consent, screening, enrollment and ongoing participation, each step can reduce the pool of recruitable patients. Protocol burden, eligibility requirements, travel, biomarker testing, physician referral barriers, perceptions of benefit-risk and competing care or trial options can all influence participation. Direct site and investigator insights can help identify these barriers and assess how well a protocol aligns with patients seen in clinical practice. Attendees will learn how to optimize for enrollment velocity rather than site count, use real-time operational signals to course-correct and establish predefined triggers for intervention. This webinar will explore how recruitment intelligence can identify why referrals are not converting, where